Trilogy 3 is the third and likely the last installment of live shows with Chick Corea’s legendary trio of bassist Christian ...

Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics ("Ambry"), which closed on February 3, 2025. Combined with $260 million of capital provided in ...

We all have that one brand we’re loyal to. But, even if you’re a Brooks diehard, might I make a case for the Saucony Tempus 2? A lightweight trainer with super foam cushioning, the Tempus 2 is ...

Tempus AI has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Insider Activity ...

CHICAGO, February 18, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the ...

Tempus AI announced a collaboration with the Institute for Follicular Lymphoma Innovation. The goal of the collaboration is to advance targeted therapy development for follicular lymphoma by ...

In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other health information services stocks. Health Information Services stocks have become a key ...

Tempus is expected to releases its 2024 fiscal-year fourth-quarter earnings report after the market closes. Analysts estimate a loss per share of 20 cents and revenue of $203.12 million. Get 5 ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health technology company announced a collaboration with the Institute for Follicular ...